Shouyao Holdings Gets Ethics Approval for SY-5933 Phase Ib/II Study in KRAS G12C Mutated Tumors
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced that it has received ethical approval...
SHA: 688197
Shouyao Holdings Unveils RMB787 Million Investment in Beijing BioPark R&D and GMP Facility
Shanghai-listed biopharmaceutical company Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) has announced plans to invest...
Shouyao Holdings Adjusts Development Strategy for SY-1530, Halts Monotherapy Clinical Trials
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced a strategic adjustment regarding its...
Shouyao Holdings Receives Clinical Trial Approval for SY-7166 in Treating Multiple Myeloma
Shouyao Holdings (Beijing) Co., Ltd, a biopharmaceutical company headquartered in Beijing and listed on the...
Shouyao Holdings Receives Ethical Approval for Phase III Study of ALK Inhibitor SY-3505
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received ethical...
Shouyao Holdings Receives CDE Approval for Phase II Study of Third-Generation ALK Inhibitor
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received clinical...
Shouyao Holdings Receives Approval for CT-3505 ALK Inhibitor Study in NSCLC
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced it has received ethical approval from...